<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01757288</url>
  </required_header>
  <id_info>
    <org_study_id>STU 062012-053</org_study_id>
    <nct_id>NCT01757288</nct_id>
  </id_info>
  <brief_title>Phase I/II NabPaclitaxel, Paclitaxel&amp;Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC</brief_title>
  <official_title>A RANDOMIZED PHASE I/II STUDY OF NAB-PACLITAXEL, OR PACLITAXEL, PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY FOLLoWED BY CONSOLIDATION IN PATIENTS WITH FAVORABLE PROGNOSIS INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose this phase I/II study to use weekly Nab-Paclitaxel (Abraxane) and
      carboplatin with concurrent radiation in local-regionally advanced lung cancer. There are no
      published human studies combining Nab-Paclitaxel (Abraxane) with radiation. The investigators
      will first confirm the tolerated dose (TD) of concurrent Nab-Paclitaxel (Abraxane) at
      50mg/m2, and then will begin enrolling patients into the phase II component using either
      Nab-Paclitaxel (Abraxane) at the TD with carboplatin concurrent with daily radiation or
      paclitaxel with with carboplatin concurrent with daily radiation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2013</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year overall survival from randomization for patients receiving carboplatin/paclitaxel or carboplatin/nab-paclitaxel with radiation therapy</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the feasibility of concurrent carboplatin/nab-paclitaxel and radiation therapy</measure>
    <time_frame>60 days of the start of treatment</time_frame>
    <description>Safety is measured by the rate of grade 3 or higher radiation related esophagitis or pulmonary toxicity or chemotherapy related grade 4 hematological or other non-hematological toxicities occurring within 60 days of the start of treatment; compliance is defined as the completion of the treatment regimen with no more than minor variations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response rate for patients receiving carboplatin/paclitaxel or carboplatin/nab-paclitaxel with radiation therapy</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the progression-free survival for patients receiving carboplatin/paclitaxel or carboplatin/nab-paclitaxel with radiation therapy</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the median overall survival for patients receiving carboplatin/paclitaxel or carboplatin/nab-paclitaxel with radiation therapy</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life (QOL) of patients receiving either nab-paclitaxel or paclitaxel when given with concurrent radiotherapy</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlate outcomes (survival, toxicity, QOL) with biological parameters</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER</condition>
  <arm_group>
    <arm_group_label>PACLITAXEL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PACLITAXEL PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAB-PACLITAXEL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NAB-PACLITAXEL PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NAB-PACLITAXEL</intervention_name>
    <arm_group_label>NAB-PACLITAXEL</arm_group_label>
    <other_name>Abraxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PACLITAXEL</intervention_name>
    <arm_group_label>PACLITAXEL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically documented NSCLC; Patients must be M0. Patients with
             T1-T2 with N2 or T3N1-2 are eligible, if inoperable. Patients with T4 with any N or
             any T with N2 or N3 disease are eligible if unresectable.

          -  Patients with tumors adjacent to a vertebral body are eligible as long as all gross
             disease can be encompassed in the radiation boost field. The boost volume must be
             limited to &lt; 50% of the ipsilateral lung volume.

          -  Patients with Zubrod performance status 0-1

          -  Adequate hematologic function

          -  FEV1 with ≥ 1200 cc or ≥ 50% predicted

        Exclusion Criteria:

          -  Prior systemic chemotherapy (for lung cancer) and/or thoracic/neck radiotherapy for
             any reason and/or surgical resection of present cancer

          -  Exudative, bloody, or cytologically malignant effusions

          -  Prior therapy with any molecular targeted drugs (for lung cancer)

          -  Active pulmonary infection not responsive to conventional antibiotics

          -  Clinically significant cardiovascular event (e.g. myocardial infarction, superior vena
             cava syndrome (SVC), New York Heart Association (NYHA) classification of heart disease
             &gt;2 (see Appendix B) within 3 months before entry; or presence of cardiac disease that,
             in the opinion of the Investigator, increases the risk of ventricular arrhythmia.

          -  Patients with &gt; grade 1 neuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hak Choy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hak Choy, MD</last_name>
    <phone>214-645-8525</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean Wu, MSN</last_name>
    <phone>214-633-1753</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuhchyau Chen, MD</last_name>
      <phone>585-275-2171</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liza Villaruz, MD</last_name>
      <phone>877-470-7241</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Spigel, MD</last_name>
      <phone>877-691-7274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Attia, MD</last_name>
      <phone>877-936-8422</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2012</study_first_submitted>
  <study_first_submitted_qc>December 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2012</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

